Should hormone therapy be continued in patients who develop hormone-resistant metastatic prostate cancer (HRPC)?
Hormone therapy should be continued in patients with HRPC. 6.2.2. Is secondary hormone therapy beneficial in patients with HRPC? Treatment with prednisone 5 mg twice daily should be considered for patients with symptomatic, advanced stage HRPC. 6.2.3. Is radiotherapy beneficial in patients with HRPC? A single dose of 8 Gy is recommended for patients with a limited number (1-3) of painful bone metastases. Use of radionuclides may be considered for patients with multiple painful bone metastases for whom conventional analgesics are insufficient, local radiotherapy is not possible, and chemotherapy is no longer an option. 6.2.4. Is chemotherapy beneficial for patients with HRPC? Patients with HRPC may be offered treatment with docetaxel given at a dose of 75 mg/m2 every 3 weeks combined with prednisone given at a dose of 5 mg twice daily. The combination of docetaxel and estramustine is not recommended given the increased risk of adverse events. Asymptomatic patients with HRPC who refuse d
Related Questions
- Which patients with locally advanced prostate cancer will benefit from adjuvant or neoadjuvant hormone therapy with radiotherapy?
- What are the expected outcomes of adjuvant or neoadjuvant hormone therapy in patients with localised prostate cancer?
- When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?
